DS-2741a Phase I Study- A Three-part First-in-human Study: Single Ascending Dose and Multiple Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-2741a After Subcutaneous Injection in Healthy Japanese Male Subjects, and Single Dose Study to Assess the Pharmacokinetics, Safety, Pharmacodynamics and Efficacy of DS-2741a After Subcutaneous Injection in Japanese Subjects With Moderate to Severe Atopic Dermatitis.
Latest Information Update: 19 Feb 2024
At a glance
- Drugs DS 2741a (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
Most Recent Events
- 16 Jun 2021 Status changed from active, no longer recruiting to discontinued.
- 20 Aug 2020 Status changed from recruiting to active, no longer recruiting.
- 16 Jan 2020 Status changed from not yet recruiting to recruiting.